These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1245879)

  • 1. Letter: Loculation as a contraindication to intracavitary 32P-chromic phosphate therapy.
    Vider M; Deland FH; Maruyama Y
    J Nucl Med; 1976 Feb; 17(02):150-1. PubMed ID: 1245879
    [No Abstract]   [Full Text] [Related]  

  • 2. Loculation as a contraindication intracavitary 32P-chromic phosphate therapy.
    Taylor A; Baily NA; Halpern SE; Ashburn WL
    J Nucl Med; 1975 Apr; 16(4):318-9. PubMed ID: 1113189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic intraperitoneal 32P: a clinical assessment of the dynamics of distribution.
    Kaplan WD; Zimmerman RE; Bloomer WD; Knapp RC; Adelstein SJ
    Radiology; 1981 Mar; 138(3):683-8. PubMed ID: 7465847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 32P following negative second-look laparotomy for epithelial ovarian cancer.
    Rogers L; Varia M; Halle J; Freddo J; Qaqish B; O'Keefe T; Fowler W
    Gynecol Oncol; 1993 Aug; 50(2):141-6. PubMed ID: 8375727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer.
    Powell JL; Kirchner AB
    J Med Assoc Ga; 1984 Jan; 73(1):21-5. PubMed ID: 6707541
    [No Abstract]   [Full Text] [Related]  

  • 6. Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma.
    Wilkinson RH
    J Nucl Med; 1996 Apr; 37(4):636-9. PubMed ID: 8691256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
    Potter ME; Partridge EE; Shingleton HM; Soong SJ; Kim RY; Hatch KD; Austin JM
    Gynecol Oncol; 1989 Mar; 32(3):314-8. PubMed ID: 2920951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma.
    Piver MS; Lele SB; Bakshi S; Parthasarathy KL; Emrich LJ
    Am J Clin Oncol; 1988 Oct; 11(5):515-9. PubMed ID: 3177251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal distribution imaging prior to chromic phosphate (P-32) therapy in ovarian cancer patients.
    Tulchinsky M; Eggli DF
    Clin Nucl Med; 1994 Jan; 19(1):43-8. PubMed ID: 8137583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution and tissue dose of intraperitoneally administered radioactive chromic phosphate (32P) in New Zealand white rabbits.
    Leichner PK; Rosenshein NB; Leibel SA; Order SE
    Radiology; 1980 Mar; 134(3):729-34. PubMed ID: 7355227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of intraperitoneal implants in mice using 32P or 60Co.
    Shaeffer J; El-Mahdi AM; Peeples WJ; Constable WC
    Int J Nucl Med Biol; 1977 Jan; 4(1):77-9. PubMed ID: 266485
    [No Abstract]   [Full Text] [Related]  

  • 12. Peritoneoscintigraphy in detection of improper placement of peritoneal catheter into bowel lumen prior to chromic phosphate P-32 therapy. A case report.
    Neutze J; Van Nostrand D; Major W
    Clin Nucl Med; 1985 Nov; 10(11):777-9. PubMed ID: 4075668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Endoperitoneal radioisotope therapy of malignant epithelial tumors of the ovary].
    Tardy A; Boidi-Trotti A
    Minerva Ginecol; 1984 Apr; 36(4):199-201. PubMed ID: 6462522
    [No Abstract]   [Full Text] [Related]  

  • 14. Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications.
    Walton LA; Yadusky A; Rubinstein L
    Int J Radiat Oncol Biol Phys; 1991 May; 20(5):939-44. PubMed ID: 2022522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of scintigraphic and contrast peritoneography in gynecologic malignancies.
    Yoonessi M; Abdel-Dayem HM; Shalaby OF
    Diagn Gynecol Obstet; 1982; 4(1):75-8. PubMed ID: 7075451
    [No Abstract]   [Full Text] [Related]  

  • 16. Dose estimation to the infant from breast milk following intraperitoneal administration of chromic phosphate 32P for the treatment of early ovarian cancer.
    Sharma SC; Osborne RP; Jose B; Carlson JA
    Health Phys; 1984 Sep; 47(3):452-4. PubMed ID: 6500947
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant intraperitoneal chromic phosphate therapy in a woman with early ovarian carcinoma and pelvic infection with resulting catastrophic complications.
    McGowan L
    Clin Nucl Med; 1994 Aug; 19(8):696-8. PubMed ID: 7955749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracavitary use of radioactive colloidal phosphorus 32 in the treatment of epithelial ovarian cancer.
    Saul HM; Sedlacek TV; Heller PB; Glassburn JR; Riva J; Bertoli R; Maslack M; Lin JK
    J Am Osteopath Assoc; 1996 Dec; 96(12):727-32. PubMed ID: 9111774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body distribution of radioactivity after intraperitoneal administration of 32P colloids.
    Boye E; Lindegaard MW; Paus E; Skretting A; Davy M; Jakobsen E
    Br J Radiol; 1984 May; 57(677):395-402. PubMed ID: 6722434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy.
    Pattillo RA; Collier BD; Abdel-Dayem H; Ozker K; Wilson C; Ruckert AC; Hamilton K
    J Nucl Med; 1995 Jan; 36(1):29-36. PubMed ID: 7799078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.